Search Results

You are looking at 11 - 20 of 148 items for :

  • "prostate-specific antigen" x
  • Refine by Access: All x
Clear All
Full access

Applying Quality Indicators to Examine Quality of Care During Active Surveillance in Low-Risk Prostate Cancer: A Population-Based Study

Narhari Timilshina, Antonio Finelli, George Tomlinson, Beate Sander, and Shabbir M.H. Alibhai

low-risk PC, these findings were not specific to AS. 17 A study from Michigan examined the frequency of follow-up prostate-specific antigen (PSA) testing and prostate biopsy among men managed with AS, 18 finding wide variation between medical

Full access

Understanding and Utilizing Patient Preferences in Cancer Treatment Decisions

Peter A. Ubel

figure out which treatment is best for the patient?” he said. Figure 1. An example of patient preference–based dialogue for recommendations. Abbreviation: PSA, prostate-specific antigen. The Typical Conversation Dr. Ubel said that

Full access

Use of Postprostatectomy Radiation Therapy at an NCI-Designated Comprehensive Cancer Center

Jeffrey M. Martin, Tianyu Li, Matthew E. Johnson, Colin T. Murphy, Alan G. Howald, Marc C. Smaldone, Alexander Kutikov, David Y.T. Chen, Rosalia Viterbo, Richard E. Greenberg, Robert G. Uzzo, and Eric M. Horwitz

pathologic assessment of the surgical specimen (T3 disease [extracapsular extension or seminal vesicle invasion], a positive margin, or Gleason score 8–10). A detectable prostate-specific antigen (PSA) level was allowed in the adjuvant definition as long as

Full access

Prostate Cancer Early Detection

Mark H. Kawachi, Robert R. Bahnson, Michael Barry, J. Erik Busby, Peter R. Carroll, H. Ballentine Carter, William J. Catalona, Michael S. Cookson, Jonathan I. Epstein, Ruth B. Etzioni, Veda N. Giri, George P. Hemstreet III, Richard J. Howe, Paul H. Lange, Hans Lilja, Kevin R. Loughlin, James Mohler, Judd Moul, Robert B. Nadler, Stephen G. Patterson, Joseph C. Presti, Antoinette M. Stroup, Robert Wake, and John T. Wei

baseline prostate-specific antigen (PSA) value was found to be a stronger predictive factor than a positive family history or being of African-American heritage. 5 Men who undergo regular PSA tests have a higher chance of undergoing a prostate biopsy and

Full access

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical Outcomes

Rahul Aggarwal, Tian Zhang, Eric J. Small, and Andrew J. Armstrong

prostate-specific antigen (PSA) expression, and upregulation of CD56 can help distinguish NEPC from prostatic adenocarcinoma. However, significant overlap and heterogeneity may occur, especially in cases of mixed histologies or with poorly differentiated

Full access

Recent Developments in the Management of Advanced Prostate Cancer

Presented by: Sandy Srinivas

Prostate cancer can evolve from clinically localized disease to biochemically resistant disease (signaled by an increase in prostate-specific antigen [PSA]). The disease can then progress to nonmetastatic castration-sensitive prostate cancer (CSPC

Full access

Prostate Cancer

James Mohler, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony D'Amico, James A. Eastham, Charles A. Enke, Daniel George, Eric Mark Horwitz, Robert P. Huben, Philip Kantoff, Mark Kawachi, Michael Kuettel, Paul H. Lange, Gary MacVicar, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Bruce J. Roth, Dennis C. Shrieve, Matthew R. Smith, Sandy Srinivas, Przemyslaw Twardowski, and Patrick C. Walsh

cancer in men. 1 Experts generally believe that these changes resulted from prostate-specific antigen (PSA) screening that detected many early-stage prostate cancers. For example, the percentage of patients with low-risk disease has increased (45.3% in

Full access

New Treatment Options in Castration-Resistant Prostate Cancer

Andrew J. Armstrong

prostate-specific antigen (PSA) levels and local therapy, and then to nonmetastatic CRPC ( Figure 1 ). They move through first, second, and third lines of therapies, often sequencing through secondary hormonal strategies such as antian-drogens (eg

Full access

PSA Screening for Prostate Cancer: Why Saying No is a High-Value Health Care Choice

Timothy J. Wilt and Philipp Dahm

Few health issues have produced more controversy than prostate-specific antigen (PSA) screening for prostate cancer. Screening and early treatment for screen-detected disease may provide large personal and public health benefits. Prostate cancer

Full access

Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population

Daphne Y. Lichtensztajn, John T. Leppert, James D. Brooks, Sumit A. Shah, Weiva Sieh, Benjamin I. Chung, Scarlett L. Gomez, and Iona Cheng

widely from indolent to fatal. To facilitate prognostication and disease management, localized PCa can be further classified into low, intermediate, and high risk of progression based on Gleason score, stage, and prostate-specific antigen (PSA) level at